Results 121 to 130 of about 413,499 (385)

Methylglyoxal induces cardiac dysfunction through mechanisms involving altered intracellular calcium handling in the rat heart [PDF]

Chemico-Biological Interactions, 2024, 394, pp.110949
Methylglyoxal (MGO) is an endogenous, highly reactive dicarbonyl metabolite generated under hyperglycaemic conditions. MGO plays a role in developing pathophysiological conditions, including diabetic cardiomyopathy. However, the mechanisms involved and the molecular targets of MGO in the heart have not been elucidated.
arxiv   +1 more source

The challenge of cardiomyopathy

Journal of the American College of Cardiology, 1989
The combined clinical and pathophysiologic characteristics and diagnostic features as well as current concepts of pathogenesis, therapy and prevention of the principal forms of cardiomyopathy are reviewed. These include hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy and specific cardiac muscle disease.
Walter H. Abelmann, Beverly H. Lorell
openaire   +3 more sources

Homocysteine Promotes the Pathogenesis of Atherosclerosis through the Circ‐PIAS1‐5/miR‐219a‐2‐3p/TEAD1 Axis

Advanced Science, EarlyView.
A model is schematically represented for the major molecular mechanisms by which homocysteine (Hcy) accelerates the nuclear export of circ‐PIAS1‐5, which regulates atherosclerosis by acting as a competing endogenous RNA for miR‐219a‐2‐3p. Hcy enrichment of circ‐PIAS1‐5 leads to YTHDC1 binding to circ‐PIAS1‐5 and promotes its intracellular localization ...
Shengchao Ma, Fei Ma, Ning Ding, Lin Xie, Anning Yang, Jiangyong Shen, Yun jiao, Kai Wu, YueE Chai, Zhigang Bai, Jiantuan Xiong, Nan Li, Huiping Zhang, Yideng Jiang   +13 more
wiley   +1 more source

Cardiomyocyte‐Enriched USP20 Ameliorates Pathological Cardiac Hypertrophy by Targeting STAT3 Deubiquitination

Advanced Science, EarlyView.
Cardiomyocyte‐enriched USP20 regulates the K63‐linked ubiquitination of STAT3, and the cardiomyocyte‐specific USP20‐STAT3‐CARM1 axis exerts a protective role in cardiac hypertrophy. Targeting USP20 through cardiac‐specific gene therapy presents a promising strategy for the treatment of cardiac hypertrophy.
Lingfeng Zhong, Shanshan Dai, Fan Yu, Guo‐Ping Shi, Qinyan Gong, Yucong Zhang, Jingsi Duan, Zhengyin Lou, Zhixuan Tang, Fuzhe Gong, Derong Chen, Liya Hou, Xinyang Hu, Jinghai Chen, Jian'an Wang, Deling Yin   +15 more
wiley   +1 more source

Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy

Frontiers in Physiology, 2020
Familial dilated cardiomyopathy (DCM) is mostly caused by mutations in genes encoding cytoskeletal and sarcomeric proteins. In the pediatric population, DCM is the predominant type of primitive myocardial disease.
Josè Manuel Pioner, Alessandra Fornaro, Raffaele Coppini, Nicole Ceschia, Leonardo Sacconi, Maria Alice Donati, Silvia Favilli, Corrado Poggesi, Iacopo Olivotto, Cecilia Ferrantini   +9 more
doaj   +1 more source

Real-World Data Analysis of Implantable Cardioverter Defibrillator (ICD) in Patients with Hypertrophic Cardiomyopathy (HCM) [PDF]

arXiv, 2020
Background: One of the common causes of sudden cardiac death (SCD) in young people is hypertrophic cardiomyopathy (HCM) and the primary prevention of SCD is with an implantable cardioverter defibrillators (ICD). Concerning the incidence of appropriate ICD therapy and the complications associated with ICD implantation and discharge, patients with ...
arxiv  

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy

Circulation, 2018
Background: A better understanding of the factors that contribute to heterogeneous outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically needed to improve patient management and outcomes.
Carolyn Y. Ho, S. Day, E. Ashley, M. Michels, A. Pereira, D. Jacoby, Allison L. Cirino, J. Fox, N. Lakdawala, J. Ware, C. Caleshu, A. Helms, S. Colan, F. Girolami, F. Cecchi, C. Seidman, G. Sajeev, J. Signorovitch, Eric M. Green, I. Olivotto   +19 more
semanticscholar   +1 more source

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

European Journal of Heart Failure, 2020
Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR‐CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT).
T. Damy, P. García-Pavía, M. Hanna, D. Judge, G. Merlini, B. Gundapaneni, T. Patterson, S. Riley, J. Schwartz, M. Sultan, R. Witteles   +10 more
semanticscholar   +1 more source

Arrhythmogenic cardiomyopathy

Orphanet Journal of Rare Diseases, 2016
Arrhythmogenic cardiomyopathy (AC) is a heart muscle disease clinically characterized by life-threatening ventricular arrhythmias and pathologically by an acquired and progressive dystrophy of the ventricular myocardium with fibro-fatty replacement. Due to an estimated prevalence of 1:2000-1:5000, AC is listed among rare diseases. A familial background
PILICHOU, KALLIOPI, THIENE, GAETANO, BAUCE, BARBARA, Rigato, Ilaria, Lazzarini, Elisabetta, MIGLIORE, FEDERICO, PERAZZOLO MARRA, MARTINA, Rizzo, Stefania, Zorzi, Alessandro, DALIENTO, LUCIANO, CORRADO, DOMENICO, BASSO, CRISTINA   +11 more
openaire   +3 more sources

Leucine‐Rich Repeat‐Containing G Protein‐Coupled Receptor 6 Ameliorates Pressure Overload‐Induced Cardiac Hypertrophy by Regulating Cardiomyocyte Metabolic Reprogramming

Advanced Science, EarlyView.
LGR6 overexpression ameliorates cardiac hypertrophy by regulating metabolic reprogramming through USP4‐PPARα pathway. Abstract Metabolic reprogramming is a pivotal mechanism in the pathogenesis of pathological cardiac hypertrophy. Leucine‐rich repeat‐containing G protein‐coupled receptor 6 (Lgr6) has emerged as a significant player in cardiovascular ...
Mengmeng Zhao, Jianfang Liu, Shanshan Peng, Zihui Zheng, Siqi Liu, Jun Wan, Yao Xu, Menglong Wang   +7 more
wiley   +1 more source